Retrospective analysis of safety and feasibility of a 3 days on/11 days off temozolomide dosing regimen in recurrent adult malignant gliomas.
- Authors
- Type
- Published Article
- Journal
- CNS Oncology
- Publisher
- Future Medicine
- Volume
- 3
- Issue
- 4
- Pages
- 257–265
- Identifiers
- DOI: 10.2217/cns.14.29
- Source
- Kesari Lab
- License
- Unknown